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• Total cholesterol, triglycerides, HDL cholesterol, LDL cholesterol, and calculated non-HDL cholesterol (=total – HDL cholesterol) constitute the primary lipid
panel for estimating risk of atherosclerotic cardiovascular disease (ASCVD) and can be measured in the nonfasting state.
• LDL cholesterol is the primary target of lipid-lowering therapies.• Lipoprotein(a)-cholesterol is part of measured or calculated LDL cholesterol and lipoprotein(a) should be measured at least once in all patients.
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• Residual risk of ASCVD even under optimal LDL-lowering treatment should be also assessed by non-HDL cholesterol or apolipoprotein B, especially in patients
with mild-to-moderate hypertriglyceridemia (2-10 mmol/L).
• Non-HDL cholesterol includes the assessment of remnant lipoprotein cholesterol and shall be reported in all standard lipid panels.• Laboratories shall flag abnormal lipid values with reference to therapeutic decision thresholds.








A B S T R A C T
The joint consensus panel of the European Atherosclerosis Society (EAS) and the European Federation of Clinical
Chemistry and Laboratory Medicine (EFLM) recently addressed present and future challenges in the laboratory
diagnostics of atherogenic lipoproteins. Total cholesterol, triglycerides, HDL cholesterol, LDL cholesterol, and
calculated non-HDL cholesterol (=total – HDL cholesterol) constitute the primary lipid panel for estimating risk
of atherosclerotic cardiovascular disease (ASCVD) and can be measured in the nonfasting state. LDL cholesterol
is the primary target of lipid-lowering therapies. For on-treatment follow-up, LDL cholesterol shall be measured
or calculated by the same method to attenuate errors in treatment decisions due to marked between-method
variations. Lipoprotein(a)-cholesterol is part of measured or calculated LDL cholesterol and should be estimated
at least once in all patients at risk of ASCVD, especially in those whose LDL cholesterol decline poorly upon statin
treatment. Residual risk of ASCVD even under optimal LDL-lowering treatment should be also assessed by non-
HDL cholesterol or apolipoprotein B, especially in patients with mild-to-moderate hypertriglyceridemia
(2–10 mmol/L). Non-HDL cholesterol includes the assessment of remnant lipoprotein cholesterol and shall be
reported in all standard lipid panels. Additional apolipoprotein B measurement can detect elevated LDL particle
numbers often unidentified on the basis of LDL cholesterol alone. Reference intervals of lipids, lipoproteins, and
apolipoproteins are reported for European men and women aged 20–100 years. However, laboratories shall flag
abnormal lipid values with reference to therapeutic decision thresholds.
1. Introduction
In the new era of very low LDL-cholesterol (LDLC) concentrations,
achievable with more intensive and novel lipid-lowering therapies, in-
creasing attention is being focused on the assessment of lipid-related
residual risk of atherosclerotic cardiovascular disease (ASCVD) using
additional biomarkers beyond LDLC [1].
An important prerequisite to address present and future challenges
of ASCVD prevention is the harmonisation of serum lipid and lipopro-
tein profiles produced by established and emerging laboratory tests and
techniques. To that end, the multidisciplinary consensus panel of the
European Atherosclerosis Society (EAS) and the European Federation of
Clinical Chemistry and Laboratory Medicine (EFLM) recently published
recommendations on the quantification of atherogenic lipoproteins in
nonfasting and fasting blood samples [1,2]. This article summarizes the
consensus-based recommendations of this expert panel which aimed to
provide appropriate guidance on the pre-analytical, analytical, and
post-analytical phases of laboratory testing of atherogenic lipoproteins.
The key recommendations are given in Table 1. Based on the Co-
penhagen General Population Study [3], reference nonfasting con-
centrations for lipids and (apo)lipoproteins are reported for 54,129
European women and 42,126 European men aged 20–100 years and not
on lipid-lowering therapy in Tables 2-3.
2. Which atherogenic lipoproteins should be measured?
2.1. LDL particles
Assessment of LDLC is a key component of the management of risk
of ASCVD [4–6]. Circulating LDL particles are highly atherogenic and
there is a direct, graded relationship between LDLC concentration and
the incidence of ASCVD observed in randomized controlled trials,
prospective epidemiological cohort studies, and Mendelian randomi-
zation studies [7,8].
Despite the overwhelming evidence that LDLC-targeted therapies
effectively reduce ASCVD in the population, many individuals experi-
ence ASCVD-related events or progression of atherosclerosis despite not
having elevated LDLC or even concentrations< 1.8 mmol/L [9]. This
residual risk indicates that a focus solely on the measurement of LDLC is
not an optimal strategy for all patients, in part explained by accumu-
lating evidence that the number of LDL particles (LDLP) measured by
lipoprotein subfractionation techniques is more strongly causally re-
lated to ASCVD than the cholesterol content of the particles [9,10].
All LDL particles are atherogenic, but their concentration is not al-
ways reflected by LDLC measurement because the cholesterol content in
the particles can vary widely between individuals according to the
continuous remodeling of lipoproteins in blood [10]. Small lipid-de-
pleted LDL subfractions contain less cholesterol than larger ones. They
are typically predominant in patients with moderately elevated trigly-
ceride (TG) concentrations or related conditions, such as diabetes and
the metabolic syndrome, without necessarily having high LDLC con-
centration [11]. These compacted LDL particles are the products of
exchange of cholesteryl esters with TG from larger, TG-rich very low-
density lipoprotein (VLDL) particles (Fig. 1). Concomitantly, smaller
high-density lipoprotein (HDL) particles are also formed in this
pathway, as typically manifested in the atherogenic dyslipidemic triad
involving hypertriglyceridemia, increased small dense LDLP, and low
HDL-cholesterol (HDLC) concentration [11].
While earlier studies emphasized the atherogenicity of small LDL
particles, it is now recognized that all LDL particles are atherogenic,
regardless of size [10]. Thus, the primary focus of treatment should
remain the reduction of the number (concentration) of LDL particles,
without efforts to distinguish between large and small LDL subfractions
[1]. Measurement of apolipoprotein B (apoB), the major protein com-
ponent of LDL, or advanced measurement of LDLP (not yet widely
available) can also be used to assess the number of LDL particles
[10,12].
The total cholesterol (TC) to HDLC ratio has been proposed as a
surrogate marker of the number of LDL particles – associated with low
HDLC and hence higher TC/HDLC ratio in individuals with atherogenic
dyslipidemia [10]. The TC/HDLC ratio may be considered as an alter-
native to LDLP for risk estimation, but not for diagnosis or as ther-
apeutic decision limit because a low ratio due to high HDLC can be
misleading: this may lead to assuming a low risk even if the patient has
high LDLC. The components of the ratio, TC and HDLC, have to be
managed separately.
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2.2. Remnant particles
Postprandial accumulation of TG-rich remnant particles in blood is
an important factor in atherogenesis [13,14]. These lipoproteins con-
tain a higher load of cholesterol that is not accounted for in typical
fasting lipid profiles. Nonfasting lipid profiles, therefore, can potentially
be more relevant to the estimation of an individual's cardiovascular risk
than fasting lipids since in real life the postprandial state predominates
most of our 24-h cycle [15,16].
TG-rich chylomicrons secreted from the intestine, and VLDL se-
creted from the liver, are rapidly depleted of part of their TG content
and acquire cholesteryl esters from HDL in the circulation (Fig. 1).
These cholesterol-enriched remnant particles may enter the arterial
intima and contribute to atherosclerosis, whereas nascent chylomicrons
and very large VLDL particles do not cross the endothelial layer [17].
Mendelian randomization studies suggest that life-long high serum
concentrations of TG-rich lipoproteins or their remnants are causally
associated with increased risk of ASCVD and all-cause mortality
[17,18].
Direct “homogeneous” assays have been developed to specifically
measure cholesterol in remnant particles (RemnantC) and some have
revealed significant associations of RemnantC with ASCVD [19,20]. An
alternative is to calculate RemnantC as TC – HDLC – LDLC, because
RemnantC corresponds to all cholesterol not found in LDL and HDL,
that is, in all VLDL and intermediate-density lipoproteins (IDL). In the
nonfasting state a relatively small amount of cholesterol can also be
found in chylomicron remnants. Because both newly secreted chylo-
microns and VLDL rapidly undergo lipolysis, any residual circulating
chylomicrons and VLDL can be considered remnants [17]. Direct LDLC
measurement should preferably be used in the calculation of RemnantC;
otherwise RemnantC simply equals TG/2.2 (in mmol/L) when Friede-
wald-calculated LDLC is used, i.e. TC – HDLC – (TC – HDLC – TG/2.2),
and it does not add clinical information beyond TG concentration [1];
however, it focuses the attention on the cholesterol content of remnants
rather than the TG content.
RemnantC also contributes to non-HDLC which is calculated as TC –
HDLC [1]. This term is independent of the Friedewald term and
therefore not correlated as tight with TG concentrations as calculated
RemnantC, and thus represents an additional clinically valuable
marker. RemnantC, measured or calculated, differs from non-HDLC in
that non-HDLC contains RemnantC plus LDLC and does not differentiate
between these two causal risk factors [1]. Non-HDLC also includes the
cholesterol of lipoprotein(a) [Lp(a)].
2.3. Lipoprotein(a) particles
Lp(a) is an LDL-like particle with one molecule of apoB to which an
additional apolipoprotein, apo(a), is attached. This apolipoprotein
shows considerable size polymorphism originating from a variable
number of kringle IV type 2 (KIV-2) repeats of apo(a) [21,22]. This size
polymorphism is the most important determinant of the hepatic pro-
duction rate of Lp(a): serum Lp(a) concentrations and number of KIV-2
repeats are inversely correlated, which results in marked genetic var-
iation of Lp(a) concentrations [21,22]. Elevated baseline and on-statin
treatment Lp(a) concentration above the 80th percentile of the general
population (50 mg/dL) is a strong genetic risk factor for cardiovascular
disease independent of LDLC [23,24]. This is recognized by the codes of
International Classification of Diseases for elevated Lp(a) and family
history of elevated Lp(a), introduced in response to the US National
Heart, Lung, and Blood Institute recommendation [25]. High Lp(a)




ASCVD atherosclerotic cardiovascular disease
FH familial hypercholesterolemia
HDL(C) high-density lipoprotein (cholesterol)
dHDLC direct HDL cholesterol (homogenous assay)
IDL intermediate-density lipoprotein
KIV-2 kringle IV type 2
LDL(C) low-density lipoprotein (cholesterol)
cLDLC calculated LDL cholesterol
dLDLC direct LDL cholesterol (homogenous assay)
LC-MSMS liquid chromatography tandem-mass spectrometry
Lp(a) lipoprotein(a)
NMR nuclear magnetic resonance
PCSK9 proprotein convertase subtilisin/kexin type 9
RemnantC remnant lipoprotein cholesterol
SCORE systematic coronary risk evaluation
TC total cholesterol
TG triglycerides
VLDL(C) very low-density lipoprotein (cholesterol)
Table 1
Key EAS/EFLM recommendations for testing of atherogenic lipoproteins [1,2].
Pre-preanalytical phase (test ordering)
Comprehensive testing of atherogenic lipoproteins should include tests to asses the
risk conferred by LDL particles, remnant particles and, in selected cases, Lp(a).
Preanalytical phase (test sampling)
Fasting is not routinely required for assessing the lipid profile.
Consider fasting sample when nonfasting TG are ≥4.5 mmol/L (400 mg/dL);
however, this is not a requirement.
Take 2 to 3 serial blood specimens, at least 1 week apart, to allow to average for
biological variation (importantly when test results are near the treatment
decision thresholds).a
Analytical phase (test measurement)
Follow-up of measured or calculated LDLC and non-HDLC of a patient, from baseline
to on-treatment measurements, should be ideally performed with the same
method (and preferably the same laboratory). b
Clinicians should be notified when the laboratory test changes from a method to
another.
The Martin-Hopkins equation may be preferable for calculation of LDLC in
patients with low LDLC concentration < 1.8 mmol/L (70 mg/dL) and/or TG
concentration 2.0–4.5 mmol/L (175–400 mg/dL), and in nonfasting samples.
Direct LDLC assays should be used for calculation of RemnantC and for
assessment of LDLC when TG concentration is ≥ 4.5 mmol/l (400 mg/dL).
Lp(a)-corrected LDLC should be assessed at least once in patients with suspected
or known high Lp(a), or if the patient shows a poor response to LDL-lowering
therapy.
ApoB assays currently provide the most accurate measurement of overall burden
of atherogenic particles in the fasting and nonfasting state.
Postanalytical phase (test reporting)
Laboratories should automatically calculate and report non-HDLC on all lipid
profiles; RemnantC could also be reported.
Laboratory reports should flag abnormal concentrations based on decision
thresholds.
Extremely high concentrations beyond the reference limits should alert clinicians
(interpretative commenting on test report).
Post-postanalytical phase (test interpretation and use)
LDLC is the primary target of lipid-lowering therapy.
When LDLC goal is achieved, non-HDLC or apoB should be preferred as
secondary treatment targets in patients with TG 2–10 mmol/L (175–880 mg/dL),
diabetes, obesity or metabolic syndrome.
a Avoid measurements within ~2 months after acute myocardial infarction,
acute trauma, surgery, acute infection or inflammatory illness, or pregnancy.
Patients should maintain their usual diet in the preceding 2 weeks, and avoid
strenuous exercise.
b Remove serum from cells (centrifugation) within 3 h of blood sampling,
and perform lipid measurements within 1–2 days of collection. However, before
measurement specimens can safely be stored at 4 °C for 3 days, at −20 °C for 1
month, and at −80 °C for 1–2 years.
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are also associated with a higher risk of mortality in the general po-
pulation [3].
One of the major differences between Lp(a) and LDL particles is that
LDLs are effectively lowered by statins, whereas Lp(a) is typically re-
sistant to this treatment [24]. In statin-treated patients the Lp(a)-asso-
ciated risk for ASCVD becomes an even better predictor for residual risk
as soon as the LDL-associated risk is decreased by statin therapy [24].
Although proprotein convertase subtilisin/kexin type 9 (PCSK9) in-
hibitors and other novel therapies reduce Lp(a) and may contribute to
reduction in ASCVD [26,27], it is yet unknown whether Lp(a) lowering
per se contributes to the clinical benefit of these novel therapies [25].
Although recent studies with PCSK9 inhibitors were not designed to
target patients with high Lp(a) concentrations, they nevertheless re-
vealed that patients with higher baseline Lp(a) concentration experi-
enced greater absolute reductions in Lp(a) and tended to derive greater
clinical benefit from PCSK9 inhibition [27,28]. Drugs on the horizon
that specifically target Lp(a) with an Lp(a)-lowering potential of 80%
and more will have to prove the benefit of an isolated lowering of Lp(a)
on ASCVD outcomes [29].
Recommendation.
• Comprehensive testing of atherogenic lipoproteins should use a
biomarker, or a panel of multiple markers, to assess the risk of
ASCVD associated not only with LDL particles, but also remnant
particles and, in selected cases, Lp(a) particles.
• Recommendations for selection of atherogenic lipoprotein tests in
different clinical settings are summarized in Table 4.
3. What is the standard lipid profile?
The traditional lipid profile of TC, TG, HDLC, and LDLC remains the
primary approach for diagnosis and ASCVD risk classification [30]. A
cost-efficient approach is to employ measurements of three markers
(TC, TG, HDLC) and from these calculate LDLC and non-HDLC. Re-
mnantC can also be calculated if directly measured LDLC is used in the
equation.
ApoB measurement is not usually part of the standard lipid profile
and ASCVD risk estimation models. Monogenic disorders such as
Table 2
Concentration distribution of nonfasting lipids, lipoproteins, and apolipoproteins in 54,129 women in the Copenhagen General Population Study not on lipid-
lowering therapy.
Percentiles
2.5 25 50 75 97.5
Age group mmol/L mg/dL mmol/L mg/dL mmol/L mg/dL mmol/L mg/dL mmol/L mg/dL
Triglycerides
20–39 0.45 40 0.73 65 0.98 87 1.4 121 2.8 248
40–65 0.50 44 0.84 74 1.2 103 1.7 148 3.6 317
66–100 0.59 52 0.98 87 1.4 120 1.9 170 3.8 340
Total cholesterol
20–39 3.3 127 4.2 162 4.7 182 5.3 205 6.9 267
40–65 3.8 147 5.0 193 5.6 217 6.3 244 7.9 306
66–100 4.3 166 5.5 213 6.1 236 6.8 263 8.2 317
LDL cholesterol
20–39 1.4 54 2.1 81 2.6 101 3.1 120 4.4 170
40–65 1.7 66 2.6 101 3.2 124 3.8 147 5.3 205
66–100 1.9 73 3.0 116 3.5 135 4.1 159 5.5 213
Remnant cholesterol
20–39 0.19 7.4 0.33 13 0.45 17 0.62 24 1.2 48
40–65 0.21 8.1 0.38 15 0.53 20 0.76 29 1.5 60
66–100 0.26 10 0.45 17 0.61 24 0.86 33 1.6 62
Non-HDL cholesterol
20–39 1.7 67 2.6 99 3.1 118 3.7 142 5.3 203
40–65 2.1 82 3.1 121 3.8 147 4.6 176 6.3 242
66–100 2.4 93 3.5 137 4.2 162 4.9 190 6.5 251
HDL cholesterol
20–39 0.91 35 1.3 51 1.6 61 1.9 73 2.5 98
40–65 0.93 36 1.4 55 1.7 67 2.1 80 2.8 108
66–100 0.98 38 1.5 58 1.9 72 2.2 86 3.0 117
Lipoprotein(a)
nmol/L mg/dL nmol/L mg/dL nmol/L mg/dL nmol/L mg/dL nmol/L mg/dL
20–39 1.1 1.4 5.4 4.3 15 8.5 43 22 207 97
40–65 1.6 1.5 6.8 4.9 17 9.8 60 30 242 113
66–100 1.9 1.6 7.4 5.2 19 10 64 31 250 116
Apolipoprotein B
g/L mg/dL g/L mg/dL g/L mg/dL g/L mg/dL g/L mg/dL
20–39 0.51 51 0.69 69 0.82 82 0.98 98 1.47 147
40–65 0.59 59 0.83 83 1.00 100 1.21 121 1.79 179
66–100 0.67 67 0.94 94 1.11 111 1.31 131 1.87 187
Nonfasting triglycerides (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDLC), and apolipoprotein B concentrations were measured by automated
assays (Thermo Scientific Konelab, Vantaa, Finland). Low-density lipoprotein cholesterol (LDLC) was calculated by the Friedewald equation when TG were<4
mmol/L and was measured directly (Konelab) when TG were ≥4 mmol/L. Non-HDL cholesterol was calculated as TC minus HDLC. Remnant cholesterol was
calculated as TC minus LDLC minus HDLC. The first 5592 individuals included in the Copenhagen General Population Study had lipoprotein(a) total mass measured
using a sensitive immunoturbidimetric assay from DiaSys (DiaSys Diagnostic Systems, Holzheim, Germany), while all remaining individuals in the study had
lipoprotein(a) measurements done using the apolipoprotein(a) isoform insensitive Denka Seiken assay (Denka Seiken, Tokyo, Japan) or the Roche second generation
lipoprotein(a) assay developed by Denka Seiken (Roche Diagnostics, Rotkreuz, Switzerland) [3].
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familial hypercholesterolemia (FH) can be easily recognized from the
standard lipid panel without the need to measure apoB [31,32]. In
patients with mild-to-moderate hypertriglyceridemia, defined as
2–10 mmol/L [33], elevated baseline and on-treatment apoB helps
identify the atherogenic dyslipidemia related to remnant lipoproteins
combined with small dense LDL particles that is not reflected by LDLC
and non-HDLC.
Lp(a) measurement should be considered at least once in each adult
person's lifetime to identify those with high inherited Lp(a) con-
centrations, in particular among patients with premature ASCVD, with
Table 3
Concentration distribution of nonfasting lipids, lipoproteins, and apolipoproteins in 42,126 men in the Copenhagen General Population Study not on lipid-lowering
therapy. Laboratory measurements and calculations were performed as described in the footnote of Table 2 [3].
Percentiles
2.5 25 50 75 97.5
Age group mmol/L mg/dL mmol/L mg/dL mmol/L mg/dL mmol/L mg/dL mmol/L mg/dL
Triglycerides
20–39 0.54 48 0.96 85 1.4 128 2.2 190 5.1 454
40–65 0.61 54 1.10 100 1.7 146 2.5 219 5.5 485
66–100 0.62 55 1.10 98 1.6 140 2.3 201 4.6 404
Total cholesterol
20–39 3.3 128 4.3 166 4.9 189 5.6 217 7.2 278
40–65 3.9 151 5.0 193 5.6 217 6.3 244 7.9 305
66–100 3.8 147 5.0 193 5.6 217 6.3 244 7.6 294
LDL cholesterol
20–39 1.5 58 2.4 93 2.9 112 3.5 135 5.0 193
40–65 1.8 70 2.8 108 3.4 131 4.0 155 5.4 209
66–100 1.8 70 2.7 104 3.3 128 3.9 151 5.0 193
Remnant cholesterol
20–39 0.22 8.5 0.43 17 0.64 25 0.95 37 1.8 71
40–65 0.26 10 0.51 20 0.74 29 1.1 43 2.0 76
66–100 0.27 10 0.50 19 0.71 27 1.0 39 1.7 67
Non-HDL cholesterol
20–39 2.0 76 3.0 115 3.6 140 4.4 170 6.2 238
40–65 2.4 92 3.6 137 4.3 164 5.5 213 6.6 255
66–100 2.3 89 3.4 133 4.1 158 4.8 184 6.1 237
HDL cholesterol
20–39 0.67 26 1.0 39 1.2 85 1.5 56 2.0 76
40–65 0.72 28 1.1 42 1.3 52 1.7 64 2.4 93
66–100 0.76 29 1.2 46 1.5 56 1.8 70 2.6 101
Lipoprotein(a)
nmol/L mg/dL nmol/L mg/dL nmol/L mg/dL nmol/L mg/dL nmol/L mg/dL
20–39 1.0 1.2 5.5 4.3 14 8.3 49 24 219 102
40–65 1.1 1.4 5.8 4.4 15 8.9 51 25 226 105
66–100 1.1 1.4 6.2 4.6 17 9.5 50 25 211 99
Apolipoprotein B
g/L mg/dL g/L mg/dL g/L mg/dL g/L mg/dL g/L mg/dL
20–39 0.56 56 0.81 81 0.99 99 1.22 122 1.86 186
40–65 0.67 67 0.96 96 1.16 116 1.41 141 2.04 204
66–100 0.66 66 0.93 93 1.11 111 1.32 132 1.86 186
Fig. 1. Intravascular remodeling of lipoproteins
contributing to the typical serum lipid profile of
atherogenic dyslipidemia.
TG-rich chylomicrons (CM) secreted from the intes-
tine, and VLDL secreted from the liver, are re-
modeled in the circulation primarily through the
actions of lipoprotein lipase (LPL), hepatic lipase
(HL), and cholesteryl ester transfer protein (CETP).
The hydrolysis of TG by LPL, leading to liberation of
free fatty acids (FFA), and the acquisition of choles-
teryl esters (CE) from HDL by CETP generates
smaller, cholesterol-enriched remnant particles
which are depleted of part of their TG content and
contributes to increased RemnantC concentrations
measured in serum. Higher VLDL output resulting
from FFA flux to the liver activates CETP, which re-
sults in TG enrichment of HDL and LDL through in-
creased exchange and transfer of TG and cholesteryl
ester. These cholesterol-depleted, TG-enriched LDL
and HDL particles are also modified by HL, produ-
cing smaller LDL and HDL and contributing to lower
serum concentrations of LDLC and HDLC, respectively, as typically manifested in the serum lipid profile of a patient with atherogenic dyslipidemia – frequently
accompanying insulin resistance and metabolic syndrome with increased FFA flux to the liver.
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FH, with a family history of premature ASCVD and/or elevated Lp(a),
or with recurrent ASCVD despite statin treatment [22]; Lp(a) mea-
surement may also be considered in those with aortic valve stenosis.
However, Lp(a) measurement should not be included in repeated lipid
profile measurements within the same patient, as Lp(a) concentrations
exhibit little variation over a lifetime. Exceptions from this rule are
transition to menopause, pregnancy, oral contraceptive use, renal im-
pairment, or when specific Lp(a)-lowering treatment is administered
[21]. Lp(a) concentrations do not change in response to normal food
intake and are minimally increased in inflammation, although the in-
fluence of acute illness or acute phase reactions on Lp(a) concentration
is discussed controversially [34].
Recommendation.
• The ‘standard lipid profile’ used for cardiovascular risk prediction
includes TC, TG, HDLC, LDLC, non-HDLC, and optionally – if di-
rectly measured LDLC is used – calculated RemnantC. A ‘minimal
lipid profile’ including only TC and TG can be considered in coun-
tries where costs are a major issue such as developing countries
[35].
• An ‘expanded lipid profile’ including Lp(a) or apoB should be used
in selected cases (Table 4) [35]. ‘Advanced lipid profiles’ such as
lipoprotein subclasses and apolipoprotein profiles have been in-
troduced in some laboratories but their added value in a clinical
setting still needs to be validated [1].
4. When to use fasting and nonfasting blood samples?
Fasting blood samples have previously been the standard for mea-
suring TG, because the fasting state reduces variability of TG con-
centrations and allows for a slightly more standardized LDLC estimation
with the Friedewald equation; however, a fasting sample does not
capture the average atherogenic lipid profile seen in the patient over a
24-h period [16]. In consequence, extended (8–12 h) fasting is no
longer routinely required for the determination of a lipid profile [2].
Findings from population studies showed that despite minor post-
prandial increases in TG and RemnantC, quantitative changes in other
lipids, lipoproteins, and apolipoproteins appear to be negligible in re-
sponse to the habitual meal intake for most individuals [2]. For pa-
tients, laboratories, and clinicians alike, nonfasting lipid profiles re-
present an operational simplication without significant negative
implications for prognostic, diagnostic, and therapeutic options for
ASCVD prevention [36]. Regardless, it may remain prudent to counsel
the patients to avoid an extremely high-fat or fast-food meal (e.g. a
burger, fries) in the preceding 12 h [37].
Nonfasting lipid profiles are now endorsed by several guidelines
including those in Europe, the UK, Canada, Brazil, and the US
[4–6,35,38]. Nonfasting and fasting measurements of the lipid profiles
must be viewed as complementary and not mutually exclusive. Fasting
is certainly not critical for first-time screening and general risk esti-
mation, or to diagnose an isolated hypercholesterolemia such as FH or
elevated Lp(a) without concomitant high TG [2]. Fasting is an option
when nonfasting TG are ≥4.5 mmol/L, a concentration seen in ~3–5%
of nonfasting individuals in the general population (Tables 2-3) [17],
and for the phenotypic diagnosis or therapeutic follow-up of mixed
dyslipidemia or isolated hypertriglyceridemia; however, this is not a
requirement and a random nonfasting blood sample will still best
capture the average TG concentration in a given patient. Fasting may
also be recommended for starting medications that cause severe hy-
pertriglyceridemia (e.g., isotretinoin) in genetically predisposed in-
dividuals, for patients recovering from hypertriglyceridemic pancrea-
titis, and when additional laboratory tests that require fasting or
morning samples (e.g., fasting glucose, or markers with circadian
rhythm) are requested [2]. The EFLM Preanalytical Phase Working
Group recently produced guidance on how to standardize fasting blood
sampling if needed [37,39].
Recommendation.
• Fasting is not routinely required for the determination of a lipid
profile.
• In patients in whom an initial nonfasting lipid profile reveals a TG
concentration ≥4.5 mmol/L, a repeat lipid profile in the fasting
state could be performed to assess fasting TG concentration; how-
ever, this is not a requirement.
5. Are LDLC measurements or calculations reliable?
5.1. Operational definition of LDL
Beta-quantification, the US Centers of Disease Control (CDC)
Reference Method for LDLC, combines ultracentrifugation to remove
VLDL and chylomicrons and heparin-Mn2+ precipitation to separate
LDL particles, including Lp(a), from HDL [40]. With beta-quantifica-
tion, the lipoprotein fraction in the density range of 1.006–1.063 g/mL
is defined as LDL, and the fraction in the density range of 1.063–1.21 g/
mL is defined as HDL [40]. However, it is not widely recognized that
the LDLC fraction on beta-quantification also contains the cholesterol
from IDL with density 1.006–1.019 g/mL and Lp(a) with density
1.04–1.13 g/mL. LDLC assays that attempt to specifically measure
cholesterol in LDL may, therefore, show discordant results compared to
the reference method [41].
5.2. Direct LDLC and HDLC assays
The “homogeneous” or “direct” LDLC (dLDLC) and HDLC (dHDLC)
assays have largely replaced the older ultracentrifugation and pre-
cipitation techniques, particularly for HDLC, but these measurements
cannot be generally assumed to provide the same clinical information
[40,41]. The total error of measurement combines systematic bias
(deviation from “true” value) and random imprecision. Despite im-
proved analytical precision due to automation, data indicate that results
can vary significantly between dLDLC and dHDLC assays from different
manufacturers [41]. Most discrepancies – with marked biases between
assays and the CDC Reference Methods – are observed in samples from
patients with hypertriglyceridemia> 2 mmol/L, mixed dyslipidemia,
or other conditions involving altered lipoprotein composition and re-
modeling, such as diabetes and chronic kidney disease [41]. Direct
measurements of dLDLC and dHDLC in normolipidemic samples usually
meet the National Cholesterol Education Program (NCEP) total error
goals of ≤12% and ≤13%, respectively, but total error ranged from
−26% to +32% for dLDLC and −20% to +36% for dHDLC in a
comprehensive study of different assays in dyslipidemic samples [42].
Most discordances in dyslipidemic samples are observed at lower con-
centration ranges of LDLC (< 1.8 mmol/L) and HDLC (<1.0 mmol/L)
[42]. These errors result in misclassifications with respect to ASCVD
risk assessment depending on the type of assay, as observed in accu-
racy-based external quality assessment surveys of hypertriglyceridemic
samples organized across different laboratories [43]. The biases noted
in dHDLC measurements affect the calculations of LDLC and non-HDLC,
since HDLC is used in the calculations [43].
The biases noted in dLDLC and dHDLC assays when analyzing
dyslipidemic samples suggest that non-specific cross-reaction takes
place, reflecting difficulties in selectively measuring the cholesterol in
LDL or HDL fractions when atypical lipoproteins are present. The dif-
ferent manufacturers’ direct methods do not measure the same LDL and
HDL subfractions [40,41]. This non-selectivity error is of major concern
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in the contemporary treatment era in which very low LDLC con-
centrations< 1.8 mmol/L are increasingly seen with highly efficacious
LDL-lowering therapies, and in which hypertriglyceridemic samples –
TG > 2 mmol/L seen in ~25% of individuals in the general population
(Tables 2-3) [17] – cause a greater analytical problem due to the in-
creasing prevalence of obesity, metabolic syndrome and diabetes mel-
litus [11].
5.3. Calculated LDLC
LDLC calculated with the Friedewald formula, cLDLC = TC – HDLC
– VLDL cholesterol (VLDLC), has its limitations. The equation uses a
fixed TG:cholesterol ratio (TG/2.2 in mmol/L or TG/5 in mg/dL) to
estimate VLDLC and assumes lack of chylomicrons which are more TG-
rich than VLDL [44]. Because the TG:cholesterol ratio in TG-rich lipo-
proteins progressively increases as hypertriglyceridemia becomes more
severe, the equation overestimates VLDLC and therefore underestimates
LDLC at high TG concentrations [44]. The equation is increasingly in-
accurate at TG concentrations from 2.3 to 4.5 mmol/L [44]. The error is
regarded as unacceptably large when TG are ≥4.5 mmol/L by NCEP
and EAS guidelines or already at ≥4.0 mmol/L by national consensus
in certain countries, and fasting blood samples should be used in this
condition [2]. At TG < 4.5 mmol/L nonfasting and fasting lipid pro-
files can be used alike for Friedewald cLDLC, when LDLC is not very
low.
At very low LDLC concentration ranges< 1.8 mmol/L, in which
VLDLC constitutes a relatively larger fraction of the blood cholesterol,
VLDLC overestimation at high TG concentration> 2.3 mmol/L in-
troduces a more significant error in the calculation of cLDLC [45]. The
resulting underestimation of LDLC may translate to downward mis-
classification when using guideline-recommended 1.8 mmol/L or
1.4 mmol/L thresholds for patients at high and very high cardiovascular
risk, respectively [4]. This may erroneously exclude>20% of patients
for initiation or intensification of lipid-lowering therapy [45].
A modified equation, Martin-Hopkins cLDLC = TC – HDLC – TG/
adjustable factor, which adjusts the TG/VLDLC ratio dynamically for
concentrations of TG and non-HDLC has been developed [46]. Rather
than dividing TG by a fixed factor of 5, the Martin-Hopkins equation
requires the use of a 180-cell table to match each patient's TG and non-
HDLC with 1 of 180 different factors ranging from 3.1 to 9.5, to give a
more personalized estimation of VLDLC in mg/dL [46]. These perso-
nalized TG/VLDLC ratios were determined by direct comparison of TG
to VLDLC concentrations directly measured after lipoprotein separation
by ultracentrifugation in> 106 US individuals from the Very Large
Database of Lipids Study [46]. In this database, TG and non-HDLC are
the two variables that explained most of the variance in TG/VLDLC
[46].
The novel Martin-Hopkins formula improves the accuracy of cLDLC
at various conditions including very low LDLC<1.8 mmol/L and in
nonfasting samples [47,48]. We recommend to use it preferably in the
range of TG concentrations 2.0–4.5 mmol/L wherein the Friedewald
equation is less accurate [47]. However, it is not trivial to install the
complex 180-cell approach of this formula into automated laboratory
information systems. A smartphone application (“LDL Cholesterol Cal-
culator”) has been developed to provide immediate and automated
calculation of Martin-Hopkins cLDLC by simple input of a patient's TC,
HDLC, and TG data from the standard lipid profile [49].
Direct LDLC assays should always be used when TG concentration
is ≥ 4.5 mmol/L, which is the limit of use of Friedewald and Martin-
Hopkins equations [50], although above this concentration the direct
assays may also show discordances with the CDC Reference Method and
will not necessarily result in accurate LDLC measurement in every pa-
tient. Even in normotriglyceridemic samples and in samples with
moderately elevated TG concentrations 2.0–4.5 mmol/L, dLDLC may
not always agree with Friedewald cLDLC and translate to discrepant
risk classifications as observed in fasting as well as nonfasting in-
dividuals [51]. It should be noted that most clinical trials demon-
strating the evidence base for clinical benefit of LDLC lowering have
used Friedewald cLDLC; thus it cannot be excluded that dLDLC rather
than cLDLC is the method that misclassifies risk [1]. However, the fact
that cLDLC calculated by either Friedewald or Martin-Hopkins equation
depends upon three laboratory assays, that is, TG, TC, and dHDLC,
means that three measurement errors are involved which inevitably
introduce calculation variability (Table 5).
5.4. Effect of Lp(a)-cholesterol on LDLC
The cLDLC equations and also most dLDLC assays include the cho-
lesterol content of Lp(a) [52]. Considering that an Lp(a) particle is
composed of about 30–45% of cholesterol by weight, a significant
overestimation of LDLC concentration occurs in subjects with high and
very high Lp(a) concentrations [52]; for example, Lp(a)-corrected LDLC
is only ~55–70 mg/dL in a person with LDLC concentration of 100 mg/
dL and an Lp(a) concentration of 100 mg/dL.
Lp(a)-corrected LDLC should be calculated at least once in patients
Table 4











TCa YESa Optionalb Optionalb Optionalb
HDLCc YESd YES NO NO
TG YES YES YES NO
LDLC YES YES YES YES
RemnantCa Optionale Optionale NO Optionale
Non-HDLCa YES NOf NO YESg
Additional tests
ApoBh YESg YESg NO Optionalg
Lp(a) YESi YESi Not yetj Not yetj
a In nonfasting samples this will also include cholesterol in chylomicrons and
their remnants; however, in the majority of individuals chylomicrons are rapidy
converted into remnants (within 5–10 min) after delivery from lymphs to the
blood stream.
b To be considered in a minimal lipid profile (TC and TG only) or when LDLC
is not available.
c Or ApoA-I if available.
d In combination with TC, if HDLC is entered as a separate variable in the
risk estimation model. Ratios of TC/HDLC, non-HDLC/HDLC, or apoB/apoA-I
which reflect the balance between atherogenic and neutral lipoproteins can be
considered as an alternative for risk estimation, but not for diagnosis or as
treatment targets. The components of the ratio have to be managed separately.
e RemnantC, calculated as TC – HDLC – LDLC, is all cholesterol found in TG-
rich lipoproteins VLDL, IDL, and, in the nonfasting state, additionally chylo-
micron remnants. RemnantC is included in non-HDLC, but non-HDLC does not
differentiate between LDLC and RemnantC. RemnantC is the part of non-HDLC
in addition to LDLC that needs reduction in some patients. Directly measured
LDLC should preferably be used in the calculation of RemnantC, or RemnantC
could be measured directly.
f Non-HDLC, calculated as TC – HDLC, is all cholesterol in atherogenic li-
poproteins: LDL, remnants, and Lp(a). None of the hyperlipidemias can be
characterized by non-HDLC because the composite marker does not differ-
entiate between the atherogenic lipoprotein-cholesterol fractions.
g In patients with mild-to-moderate hypertriglyceridemia, 2–10 mmol/L
(175–880 mg/dL), diabetes, obesity or metabolic syndrome.
h Or advanced LDLP measurement if available.
i At least once in each adult person's lifetime, especially in patients with
premature ASCVD (men<55 years, women<60 years), family history of
premature ASCVD and/or elevated Lp(a), FH, recurrent ASCVD despite optimal
lipid-lowering treatment.
j Unless approved treatment is available to substantially reduce Lp(a) con-
centration and Lp(a)-related risk.
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with suspected high Lp(a), particularly in African-Americans, in pa-
tients with nephrotic syndrome, in those undergoing peritoneal dialysis,
and in any patient who does not respond sufficiently to statin therapy
[1]. If a high Lp(a) concentration is indeed the cause for an apparent
non-response or low response of LDLC, then it might not be useful to
increase the dosage of statin under such conditions [1]. The correction
is as follows with Lp(a) values reported in mg/dL:
Lp(a)-corrected LDLC (mg/dL) = LDLC (mg/dL) – [Lp(a) (mg/dL) x
0.30]
Lp(a)-corrected LDLC (mmol/L) = LDLC (mmol/L) – [Lp(a) (mg/dL) x
0.0078]
At this point of time, we do not provide alternative formulas for Lp
(a) reported in nmol/L (despite a proposed rough estimate of 2-2.5x
conversion factor from mg/dL to nmol/L) [25]. It has to be recognized
that a simple conversion of Lp(a) from mg/dL to nmol/L or vice versa
has its limitations since probably most of the available immunoassays
cannot measure Lp(a) in strict molar terms due to the size heterogeneity
of apo(a) isoforms and the high probability that antibodies against apo
(a) recognize a repetitive KIV-2 epitope of apo(a) [53].
Recommendation.
• The Martin-Hopkins modified equation may be preferable for cal-
culation of cLDLC, most importantly in patients with low LDLC
concentration<1.8 mmol/L and/or TG concentrations
2.0–4.5 mmol/L, and in nonfasting samples [6].
• Direct LDLC assays should be used for calculation of RemnantC and
for assessment of LDLC when TG concentration is ≥ 4.5 mmol/L (or
≥4.0 mmol/L by national consensus in certain countries). However,
the direct assays will not necessarily result in more accurate LDLC
assessment in every patient.
• Lp(a)-cholesterol correction of measured or calculated LDLC should
be applied in patients with known or suspected high Lp(a) con-
centration, or if the patient shows a poor response to LDL-lowering
therapy.
6. LDLC test errors: are they clinically relevant?
The ranges of uncertainty across different LDLC methods are not
negligible (Table 5). Between-laboratory variation of a certain patient's
measured or calculated LDLC can range widely over the guideline-
driven critical values that determine the decision of therapeutic inter-
vention (Table 6). Depending on the method used, different treatment
decisions may be taken, or confusion may arise if the patient's samples
for monitoring are sent to different laboratories using different methods
or when a laboratory changes the method. Not uncommonly, changes in
a patient's LDLC test result over time are within the range of uncertainty
of laboratory method variation and may not be due to therapeutic in-
tervention [1].
These issues are, however, less relevant for the monitoring of the
patient by the same laboratory and method over time. In this situation,
the non-specificity bias remains constant over time and only the assay
imprecision (random error) and lot-to-lot variation are relevant, which
may not be important given that clinicians are not aiming to achieve the
LDLC targets exactly but often concentrations below it. In the present
era, the percentage of LDLC reduction is more important than achieving
specific targets, and indeed recent guidelines suggest that achievement
of a> 50% reduction in high- and very high-risk patients is paramount
irrespective of baseline LDLC concentration [4].
The risk that errors in LDLC measurement or calculation affect the
clinical decision is further attenuated by the recommendation that de-
cision to initiate a treatment, or adjusting or shifting to another treat-
ment, should not be taken on one LDLC test, but rather after multiple
repeated testing (at least two times) to allow averaging for intra-in-
dividual (biological) variation [41]. The EFLM Biological Variation
Working Group recently revised biological variation data [54,55].
Recommendation.
• Follow-up of on-treatment lipid profiles in a patient should ideally
be undertaken with the same method (and preferably in the same
laboratory) to minimize misinterpretation of treatment effect.
• Clinicians should be notified by the laboratory when the test
changes from one method to another, e.g. through newsletters. This
will enhance clinicians' awareness of changes in methods as a po-
tential cause of implausible test results.
• Assay methods and their limitations should always be described in any
publication of clinical trials or epidemiological studies. In meta-analyses
of associations of lipid tests with outcomes, it is critical to verify the
comparability of quantitative data of the assays used in each trial.
• A patient's LDLC value close to therapeutic decision thresholds
should ideally be confirmed by repeated measurement(s) (≥2) by
the same method and then averaged. Often the repeated test value is
lower due to improved diet after the first test if the patient is told
that LDLC is elevated; in this case the second value should be ac-
cepted for decision making.
7. Are other measurements of atherogenic lipoproteins reliable?
7.1. Non-HDL cholesterol
Calculated by subtracting HDLC from TC, non-HDLC represents the
cholesterol in all particles causing cardiovascular disease, that is, LDL,
VLDL, IDL, and Lp(a); in the nonfasting state this additionally includes
Table 5
Example of between-laboratory uncertainty when lipids are measured by different methods in a hypertriglyceridemic patient.
Test Assumed total error Defined concentration in model patient Range of uncertainty
mg/dL (mmol/L) mg/dL (mmol/L)
TC 9% a 200 (5.2) 182 to 218 (4.7–5.7)
TG 15% a 250 (2.8) 212 to 288 (2.4–3.3)
dHDLC −20% to +36% b 40 (1.0) 32 to 54 (0.8–1.4)
Non-HDLC (derived from TC and dHDLC) 160 (4.1) 128 to 186 (3.3–4.8)
cLDLC (Friedewald) (derived from TC, dHDLC and TG) 110 (2.8) 70 to 144 (1.8–3.7)
cLDLC (Martin-Hopkins) (derived from TC, dHDLC, TG and non-HDLC) 122 (3.2) 91 to 151 (2.4–3.9)
dLDLC −26% to +32% b 122 (3.2) 90 to 161 (2.3–4.2)
a Based on National Cholesterol Education Program (NCEP) analytical performance criteria [41].
b Total error ranges observed by Miller et al. [42] across different dLDLC and dHDLC methods in dyslipidemic samples. The total error combines systematic bias
and random imprecision. The table is not relevant for the monitoring of a patient by the same laboratory/method over time. In this situation the bias remains constant
and only the (inevitable) imprecision is relevant. Bias should ideally be ≤ 4% for LDLC and ≤5% for HDLC to allow the methods to meet the NCEP total error goals,
≤12% and ≤13%, respectively.
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the cholesterol in chylomicrons and their remnant particles [1]. Non-
HDLC provides a more comprehensive risk assessment than LDLC in
certain individuals with hypertriglyceridemia because it adds Re-
mnantC to LDLC and, therefore, takes into account the atherogenic
potential of remnant lipoproteins [17]. However, non–HDLC cannot
substitute for RemnantC because it does not differentiate between Re-
mnantC and LDLC and Lp(a)-cholesterol. Some individuals with high
RemnantC have low LDLC and thus will have relatively low non-HDLC
if Lp(a) is also low, and if interpreting non-HDLC instead of RemnantC,
the high RemnantC will be masked in these individuals [30].
Like LDLC, non-HDLC is treatable with existing lipid-lowering
agents and there is a direct, consistent relationship between the mag-
nitude of non-HDLC lowering and cardiovascular risk reduction ob-
served in meta-analyses and trials with statins and other lipid-lowering
agents [56,57]. Guideline-recommended therapeutic goals for non-
HDLC are arbitrarily set typically at 0.8 mmol/L (30 mg/dL) higher
than LDLC goals (Table 6); this value is based on the assumption that
the “optimal” VLDLC concentration associated with the fasting TG
threshold 1.7 mmol/L is 0.8 mmol/L, as estimated by the Friedewald
formula (TG/2.2) [1,2].
Non-HDLC can be obtained in the nonfasting state and does not
require TG to be less than 4.5 mmol/L, which is the limitation for
calculation of cLDLC [44]. However, dHDLC measurement errors in
hypertriglyceridemic samples still affect the calculation of non-HDLC
and most assays limit the measurement of dHDLC to TG < 10 mmol/L.
Despite this limitation, non-HDLC yields more accurate cardiovascular
risk classification than either Friedewald cLDLC or dLDLC, and also
more consistent risk scores using different manufacturers’ assays for
dHDLC in the calculation [58]. Non-HDLC shows better correlation and
concordance with cLDLC when using the Martin-Hopkins formula
compared to the Friedewald equation in patients with atherogenic
dyslipidemia [59]. When compared to Martin-Hopkins cLDLC, non-
HDLC translates to only modest improvement for risk classification that
could change clinical management (in ~2% of individuals in a general
population), although discordance of Martin-Hopkins cLDLC and, as a
consequence, risk underestimation is still common (80–90%) in patients
with TG ≥ 4.5 mmol/L [60].
7.2. Apolipoprotein B
In contrast to the heterogeneous LDLC fraction, apoB is a clearly
defined measurand. It is the structural protein for all non-HDL lipo-
proteins and exists as 2 isoforms: apoB100, the major isoform in VLDL,
IDL, LDL, and Lp(a), and apoB48 in chylomicrons and chylomicron
remnants [12]. ApoB100 contains the ligand that binds to the LDL re-
ceptor. Since each atherogenic particle contains one molecule of apoB,
concentrations of apoB are therefore considered to be a direct measure
of the total number of lipoproteins causing cardiovascular disease, that
is, LDL, remnants, and Lp(a) [12].
ApoB quantification by automated immunoassays such as im-
munonephelometry and immunoturbidimetry can be easily im-
plemented in the clinical laboratories. These immunoassays obviate the
need for lipoprotein subfractionation techniques such as nuclear mag-
netic resonance (NMR) spectroscopy or ion mobility to quantify LDLP
and have been shown to be at least equivalent to LDLP in predicting
cardiovascular risk [61,62]. However, apoB cannot substitute for NMR-
or ion mobility-based particle size measurements and does not differ-
entiate between LDL and VLDL particle numbers [61,62]. A major im-
pediment to LDLP testing is its limited availability in the clinical la-
boratories, higher cost, and lack of standardization [63], although it
does provide additional information on other lipoproteins VLDL and
HDL, beyond LDLP.
ApoB can be measured in the nonfasting state because even at peak
postprandial concentrations, the number of chylomicron-apoB48 par-
ticles in healthy individuals is usually< 1% and the number of VLDL-
apoB100 particles is< 10% of the number of LDL-apoB100 particles
[12]. Thus, even when cross-reactivity of immunoassays to apoB48
occurs in nonfasting measurements, apoB quantification is essentially
an estimate of LDL particle number if TG and Lp(a) concentrations are
low [1]. Far higher than the maximum allowed TG concentration of
4.5 mmol/L for cLDLC, most nephelometric and turbidimetric apoB
measurements are limited to TG < 10 mmol/L due to interference of
light scattering or absorption caused by chylomicrons and large VLDLs;
a TG concentration above this limit in nonfasting blood samples is only
seen in ~0.1% of individuals in the general population [17]. Never-
theless, it is cautious to consider fasting apoB measurement when TG
concentration in the nonfasting sample is ≥ 4.5 mmol/L [2].
The International Federation of Clinical Chemistry (IFCC) and
World Health Organization (WHO) developed the SP3 reference mate-
rial, value-assigned using immunonephelometry as interim reference
method for apoB [64]. Common calibration with the IFCC/WHO SP3
reference material has reduced between-laboratory variability of apoB
measurements from>19% to< 10%, although concerns about the
variability among immunoassays and their comparability with apoB100
derived from NMR and other methods still exist [65–67]. Liquid chro-
matography tandem-mass spectrometry (LC-MSMS)-based quantifica-
tion of apolipoproteins has the potential to further improve apoB100
standardization and between-method comparability [67]. The IFCC has
therefore initiated development of LC-MSMS as candidate definitive
reference method for apoB [67]. Another advantage of LC-MSMS is that
it enables the simultaneous (multiplexed) measurement of multiple
apolipoproteins in addition to apoB100 in a single run of the assay, thus
making it possible to achieve a complete apolipoprotein profile in the
patient, including HDL- and VLDL-associated apolipoproteins for com-
prehensive characterization of dyslipidemias [68]. Although nowadays
throughput of LC-MSMS is low compared to immunoassays, automated
LC-MSMS systems are developed and will become available for im-
plementation in high-throughput clinical laboratories.
Given the improvements of standardization initiated by the IFCC
[69], measurements of apolipoproteins have the potential to meet
Table 6
Primary and secondary goals of preventive therapy according to cardiovascular









Very high < 1.4 (55)
and ≥50% reduction in LDLC
<2.2 (85) c < 0.65 (65) d
High < 1.8 (70)
and ≥50% reduction in LDLC
<2.6 (100) < 0.80 (80)
Moderate < 2.6 (100) < 3.3 (130) < 1.00 (100)
Low <3.0 (115)
Very high risk = documented ASCVD, diabetes with target organ damage
(proteinuria, retinopathy or neuropathy), or early onset type 1 diabetes of> 20
years duration, severe chronic kidney disease (GFR<30 mL/min/1.73 m2),
SCORE ≥10%; High risk = TC > 8 mmol/L (310 mg/dL), LDLC>5 mmol/L
(190 mg/dL), FH, hypertension ≥180/110 mmHg, diabetes of ≥10 years
duration without target organ damage, moderate chronic kidney disease (GFR
30–59 mL/min/1.73 m2), SCORE ≥5% and<10%.
Moderate risk = young patients with diabetes (type 1 < 35 years, type
2 < 50 years) of< 10 years duration, SCORE ≥1% and<5%.
Low risk = SCORE<1%.
To convert mmol/L to mg/dL, multiply with 38.6 for LDL and non-HDL cho-
lesterol.
a 10-year risk of fatal ASCVD as estimated using SCORE (Systematic
COronary Risk Evaluation) [4].
b Secondary target in patients with mild-to-moderate hypertriglyceridemia,
2–10 mmol/L (175–880 mg/dL) including those with obesity or metabolic
syndrome, diabetes, or chronic kidney disease.
c Discordant high non-HDLC at optimal LDLC goal reflects elevated
RemnantC> 0.8 mmol/L (30 mg/dL).
d Discordant high apoB at optimal LDLC goal reflects elevated numbers of
small, cholesterol-depleted LDL particles.
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analytical performance criteria including accuracy, harmonisation
across laboratories, unambiguous definition of the measurand, and
unequivocal test results in both normo- and dyslipidemic sera – im-
portant prerequisites for medical use of a test which can not be met
with LDLC and non-HDLC measurements or calculations.
Recommendation.
• ApoB measurement is superior to LDLC and non-HDLC measure-
ments and calculations for the assessment of exposure to athero-
genic lipoprotein particle numbers in the circulation.
• ApoB is recommended for risk assessment and may be preferred
over non-HDLC, if available, in persons with mild-to-moderate hy-
pertriglyceridemia (2–10 mmol/L), diabetes, obesity or metabolic
syndrome, or very low LDLC<1.8 mmol/L [4].
• Like non-HDLC, apoB can always be measured in the nonfasting
state and is not affected by biological TG variability.
8. Can apoB measurement replace the standard lipid profile for
monitoring of lipid-lowering therapies?
Although the traditional lipid profile of TC, TG, HDLC, and LDLC
remains essential for dyslipidemia diagnosis and ASCVD risk categor-
ization, the position of LDLC as treatment target is challenged by the
analytical performance of apoB. However, the apoB test has not yet
been completely validated for this clinical purpose according to key
criteria defined by the EFLM Test Evaluation Working Group [70] –
clinical performance, clinical effectiveness, and cost-effectiveness –
beyond analytical performance to become a medically useful test
(Table 7).
8.1. Clinical performance – risk estimation
Data and meta-analyses of prospective population-based cohort
studies [71–74] and statin trials [75,76] suggest that the clinical per-
formance of apoB and non-HDLC, although superior to LDLC in some
studies, is on average comparable to dLDLC, Friedewald cLDLC or
Martin-Hopkins cLDLC to predict risk of fatal or nonfatal ASCVD on the
population level. Risk associations are similar in nonfasting study po-
pulations than in those who did fast [72,74].
For a majority of patients in whom apoB tests correlate with LDLC,
measurement of traditional lipids should suffice to estimate risk.
However, in ~20% of individuals in whom apoB is discordantly high
with respect to population percentiles of LDLC, cardiovascular risk
tracks with apoB, suggesting that replacing LDLC by apoB would
identify more individuals with increased risk of ASCVD [74] – this
implies an overall better clinical performance compared to LDLC in
particular among this smaller subset of individuals with discordant
apoB.
8.2. Clinical effectiveness – risk reduction
The substantial residual risk that persists in LDLC-targeted therapies
even at LDLC<1.8 mmol/L has fueled the debate about considering
using apoB rather than LDLC as treatment target. Meta-analyses of
lipid-lowering trials showed that statins and other therapies which clear
apoB-containing lipoproteins by upregulating LDL receptor expression,
such as PCSK9 inhibitors, reduce cardiovascular risk proportional to the
decrease in apoB concentration observed in these trials [77,78]. Fur-
thermore, Mendelian randomization studies demonstrated that the re-
duction in cardiovascular risk associated with genetic variation in
clearance and processing of apoB-containing lipoproteins, including
LDL particles as well as TG-rich VLDL particles and their remnants, was
correlated with the change of concentration of these particles as mea-
sured by apoB rather than the cholesterol mass carried by those parti-
cles as measured by LDLC [79,80]. These findings suggest a potential
role of apoB as therapeutic target.
8.3. Cost-effectiveness – health economic benefit
Implementation of apoB assays in follow-up of lipid-lowering
therapies would impose healthcare systems and patients with yearly
extra cost, although one might consider replacing the standard lipid
profile (needed for calculation of LDLC and non-HDLC) by single
follow-up measurement of apoB in order to attenuate the rise of ex-
penses. The suggested use of apoB would be cost-effective if these tests
guide therapy to reduce the healthcare costs of ASCVD to a greater
extent than standard therapy guided by LDLC, yet the evidence base of
this approach is still incomplete (Table 7). To evaluate cost-effective-
ness of apoB-guided treatment, randomized trials should be designed in
Table 7
Contemporary evidence for the medical use of LDLC, non-HDLC, apoB, and LDLP based on essential test characteristics [1]. Test characteristics defined by the EFLM
Test Evaluation Working Group [70].
Test characteristics LDLC non-HDLC ApoB LDLP
Analytical performancea
Precise assays Yes Yes Yes Yes
Accurate assays (method independency) No No Yes No
Nonfasting measurement possible cLDLC at TG < 4.5 mmol/L Yes Yes Yes
Widely accessible assays Yes Yes Yes No
Reasonable operational costs Yes No extra measurement Yes Not yet
Clinical performanceb
Robust associations with incident ASCVD? Yes Yes Yes Yes
Novel information beyond existing markers? (Reference) Yes Yes Yes
Validated decision thresholds? No No No No
Clinical effectivenessc
Superiority to existing tests? (Reference) Probably Probably Probably
Modifiable risk association (treatment target)? Yes Yes Yes Yes
Test-guided treatment reduces ASCVD risk? Yes Probably Probably Unknown
Cost effectivenessd
Test-guided treatment saves healthcare costs? Yes Unknown Unknown Unknown
a Analytical validity: ability of the test to conform to predefined quality specifications to measure the marker of interest.
b Diagnostic or prognostic accuracy: ability of the test to consistently discriminate patients with increased risk from those with lower risk for developing ASCVD.
c Clinical utility: ability of the test to improve health outcomes of the patient under standard clinical care.
d Health-economic advantage of introducing the test in medical practice (value for money).
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which patients are randomized to receive the apoB test vs. the standard
LDLC test and the health economic outcome(s) of identifying and
treating more patients at high risk (i.e., not identified or treated when
using the standard test) is assessed [1].
Recommendation.
• At this point of time, there is insufficient evidence of benefit from
outcome studies to support the option to replace the standard lipid
profile (with calculation of cLDLC and non-HDLC) by single follow-
up measurement of apoB to guide lipid-lowering therapies.
• The clinical effectiveness of LDLC-guided management of cardio-
vascular risk is most strongly evidence-based [7,8]. All guidelines
concur that LDLC remains the primary target of lipid-lowering
strategies to prevent ASCVD [4–6]. Lowering LDLC to concentra-
tions below a target of 1.8 mmol/L in patients at high cardiovascular
risk or 1.4 mmol/L in patients at very high risk (or by ≥ 50% if
these targets cannot be attained) is of critical importance [4].
9. Should non-HDLC or apoB be used as additional tests to LDLC in
lipid-lowering strategies?
9.1. Non-HDL cholesterol
Data from concordance/discordance analyses suggest that calcula-
tion of non-HDLC is at least equally good at predicting ASCVD com-
pared with measurement or calculation of LDLC in the overall popu-
lation and statin-treated patients; it may also be superior to LDLC if
discordantly high, especially at normal or low LDLC concentrations and
in individuals with hypertriglyceridemia because it includes RemnantC
[81–83]. LDLC does not provide incremental risk prediction of ASCVD
relative to non-HDLC [81–83]. The only concern is the threshold con-
centration selected in some studies: it may be the more sensitive
threshold for non-HDLC as compared to LDLC rather than the bio-
marker which makes the difference. Guideline-based non-HDLC
thresholds have been arbitrarily defined by consensus of expert groups,
based on the assumption that a normal VLDLC concentration exists
when TG are<1.7 mmol/L, which is < 0.8 mmol/L as estimated by
the Friedewald formula [1,2]. Lowering non-HDLC thresholds leads to
upward reclassification of patients (if the goal is to reduce under-
treatment), higher thresholds lead to downward reclassification (if the
goal is to reduce overtreatment). Threshold values need to be validated
in clinical performance studies, to evaluate which values most accu-
rately classify patients within risk categories [70].
For the present purposes, the combination of non-HDLC with
Martin-Hopkins cLDLC may be considered as an appropriate strategy to
guide therapy and they can be calculated from the standard lipid profile
[1]. This may compensate for the under- or overestimation of LDLC in
terms of clinical decision making, given the uncertainty of dLDLC
measurements or the Friedewald calculation in dyslipidemic samples
when LDLC lowering approaches 1.4 mmol/L, and non-HDLC can be
used at high TG ≥ 4.5 mmol/l. However, the compromised accuracy of
dHDLC assays in samples with hypertriglyceridemia reduces the benefit
in reporting non-HDLC in some individuals in whom an apoB or LDLP
measurement may be clinically useful [1].
9.2. Apolipoprotein B
Data from concordance/discordance analyses in large case-control
and prospective cohort studies reveal that the addition of apoB to LDLC
and even to non-HDLC has the potential to improve risk prediction by
identifying more high-risk individuals [74,84–86]. This is consistent
with the notion that risk of ASCVD is more directly related to the
number of apoB-containing particles (reflected by apoB measurement)
than to the cholesterol content of lipoproteins [10]. The implication of
discordant LDLC vs. apoB (one normal, the other high) is most evident
in patients with predominant small, cholesterol-depleted LDL particles
who present with “optimal” concentrations of TC and LDLC – a profile
that is especially prevalent among individuals with the metabolic syn-
drome or diabetes and in those taking medications, such as statins and
anti-PCSK9, that reduce LDLC to a greater extent than apoB [87–89].
This necessarily results in on-treatment LDL and VLDL particle numbers
that are higher than would be anticipated from the concurrent LDLC
follow-up measurement and may explain part of residual risk among
statin-treated patients [62,90].
In patients with a moderate estimated risk score, in particular those
with additional metabolic risk factors, apoB (or LDLP) measurement as
a “risk-enhancing factor” could be useful [6]. Presence of risk-enhan-
cing factors including apoB can tip the balance toward earlier initiation
of drug treatment in shared decision making between clinician and
patient, especially in primary prevention if goals cannot be achieved
with lifestyle advice [6].
9.3. Secondary treatment target: non-HDLC or apoB?
Guidelines propose using non-HDLC or apoB as a secondary treat-
ment target in the management of patients with mild-to-moderate hy-
pertriglyceridemia (2–10 mmol/L), including patients with diabetes
[4,5]. If the primary target LDLC is at goal, but non-HDLC or apoB are
still high, attainment of all three targets will require intensified lipid-
lowering therapy, lifestyle (re)inforcement, and/or additional TG-low-
ering drugs (e.g., fibrate or omega-3 fatty acids) [4]. Addition of PCSK9
inhibition to statin therapy allows more patients to achieve non-HDLC
and apoB goals and lower risk of ASCVD, with no attenuation of benefit
at lower concentrations [88].
Which to choose as secondary target: non-HDLC or apoB? Although
apoB demonstrates competitive clinical performance compared with
non-HDLC, there is no evidence yet of significant population health-
economic benefit of intensifying pharmacological intervention aiming
to further reduce apoB at very low concentrations of LDLC [1]. For now
and until this issue is clarified, non-HDLC is an acceptable choice and it
can be used without the additional expense of extra measurement.
Recommendation.
• Use of non-HDLC or apoB should be considered as an index of the
efficacy of treatment targeted at LDLC. For the present purpose,
every lipid profile report should automatically add non-HDLC. To
improve patient comfort and compliance, there are practical ad-
vantages of this approach for follow-up without the need to fast [2].
• At TG concentration ≥4.5 mmol/L, a condition wherein use of
Friedewald cLDLC or Martin-Hopkins cLDLC is not recommended
and also dLDLC is likely to be inaccurate, use of non-HDLC calcu-
lation may be considered instead of dLDLC measurement to evaluate
therapeutic response.
10. How to report the atherogenic lipid profiles?
10.1. Threshold values
We recommend that laboratory reports should flag abnormal con-
centrations based on threshold values defined by guidelines, i.e., deci-
sion threshold to trigger therapy or to identify increased risk of ASCVD
(Table 8). For nonfasting samples, laboratories should flag abnormal TG
concentrations as ≥2 mmol/L according to the Women's Health Study,
which found that this threshold was optimal for ASCVD prediction [91].
The threshold for fasting TG at 1.7 mmol/L is 0.3 mmol/L lower than
for nonfasting TG, corresponding to the mean maximal increase in TG
following habitual food intake [2]. Nonfasting state-adjusted thresholds
for RemnantC and, consequently, also non-HDLC may be considered as
an option (Table 8). In case the patient's postprandial time in the pre-
ceding 12 h is unknown on sample reception in the laboratory, it may
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remain prudent to apply the lower fasting thresholds to draw attention
to a potential cardiovascular risk.
For LDLC, the decision threshold for initiation of therapeutic in-
tervention varies with the individual's risk score (Table 6) [4]. This
personalized reporting of optimal thresholds is difficult to implement in
laboratory reports because usually the clinical conditions and risk fac-
tors of the individual patients are not known to the laboratory per-
sonnel. We therefore propose a simplified flagging based on the
threshold for low risk only (3 mmol/L), which may be complemented
by more detailed information on risk-stratified thresholds in footnotes
on the laboratory report or by references to web-based information [2].
Given the uncertainty of measurements and calculations of LDLC
across different methods and laboratories, in hypertriglyceridemic pa-
tients the decision thresholds may not always be assumed to be uni-
versally applicable [1]. Guideline-recommended LDLC thresholds are
based on observations with Friedewald cLDLC using the older HDLC
precipitation methods which differ from dHDLC assays used nowadays.
This situation is challenging for new generation assays to meet reg-
ulations for in vitro diagnostic medical devices, requiring evidence of
clinical performance of the assays [70].
10.2. Reference limits
Usually, in laboratory reports, results of most tests are flagged if
they are below or above the age- and sex-specific reference interval
(2.5th to 97.5th percentiles). Because of the widespread unhealthy
lifestyle, in most populations the upper reference limits of TC, LDLC,
and TG are very high and far above the thresholds of increased ASCVD
risk (Tables 2-3, Fig. 2). Therefore, flagging of lipid profiles in adults
should not be based on reference limits [2]. In a pediatric setting, re-
porting age- and gender-specific reference intervals is relevant for early
identification of children with hyperlipidemia associated with pre-
mature atherosclerosis, especially FH [32].
Reference nonfasting concentrations in adults from the Copenhagen
General Population Study are reported in Tables 2-3. Reference inter-
vals in children and adolescents are available from recent population-
based cohort studies and databases [92–94]. Countries are encouraged
to establish reference intervals in their local populations, to account for
differences in lifestyle and risk factors in different European regions.
Ideally, these reference intervals should be regularly updated because
significant changes in population lipid concentrations occur mainly
related to the substantial increase in unhealthy lifestyle and obesity and
changes of analytical methods over time [95–97]. In the adoption of
published reference concentrations with known biological or analytical
sources of variation, the clinical laboratory should verify the reference
interval with its own analytical method on 20 samples drawn from its
local population under similar pre-analytical conditions [96,97]. If ≤ 2
of 20 values (≤10%) fall outside the reference interval then the interval
can be adopted [96,97]. For decision thresholds it is unnecessary to
validate them in the laboratory [97].
10.3. Alert values
Using decision thresholds for flagging will lead to many lipid pro-
files reported with flags, as with more than 50% of LDLC results (Fig. 2).
There is a risk that flagging too many results will make the physician
ignore very high concentrations and may distract from the severe
dyslipidemias, especially when used for screening in primary care. We
have considered this by defining alarming values for extreme dyslipi-
demias, where we recommend special notification and reaction from
the laboratory [2].
Extremely abnormal test results should be flagged with special alert
notifications to quickly initiate further diagnostic and possibly ther-
apeutic actions by the clinician (Table 8). For example, patients with
severe hypertriglyceridemia ≥10 mmol/L and chylomicronemia syn-
drome have high risk of acute pancreatitis but usually do not develop
premature atherosclerosis, probably because chylomicrons and large
VLDLs do not traverse the vascular endothelial barrier [33]. Lp(a)
above the 97.5th percentile (> 120 mg/dL depending on the assay)
should be noted because of very high risk for myocardial infarction and
aortic valve stenosis [2]. Any LDLC>5 mmol/L in adults or> 4
mmol/L in children should trigger investigations to rule-out FH and, if
diagnosis of FH is confirmed in the index case, cascade family screening
[31,32]. In patients with mixed hyperlipidemias, routine genetic testing
is not warranted [33]. Reflective testing can proactively assist clinicians
to rule-out common secondary causes of hyperlipidemia using
Table 8
Flagging of abnormal lipid and (apo)lipoprotein concentrations based on risk prediction thresholds and of extremely abnormal concentrations [2].
Parameter Thresholds Interpretative commenting
TG a Fasting ≥1.7 mmol/L (150 mg/dL)
Nonfasting ≥2 mmol/L (175 mg/dL)
> 10 mmol/L (880 mg/dL): severe hypertriglyceridemia with high risk of acute pancreatitis
TC ≥5 mmol/L (190 mg/dL)
LDLC ≥3 mmol/L (115 mg/dL) > 13 mmol/L (500 mg/dL): consider homozygous FH
>5 mmol/L (190 mg/dL): consider heterozygous FH
RemnantC Fasting ≥0.8 mmol/L (30 mg/dL)
Nonfasting ≥0.9 mmol/L (35 mg/dL)
Non-HDLC Fasting ≥3.8 mmol/L (145 mg/dL)
Nonfasting ≥3.9 mmol/L (150 mg/dL)
ApoB ≥1 g/L (100 mg/dL) < 0.1 g/L (10 mg/dL): genetic abetalipoproteinemia
HDLC Men ≤1 mmol/L (40 mg/dL)
Women ≤1.2 mmol/L (45 mg/dL)
ApoA-I Men ≤1.2 g/L (120 mg/dL)
Women ≤ 1.4 g/l (140 mg/dL)
< 0.1 g/L (10 mg/dL): genetic hypoalphalipoproteinemia
Lp(a) ≥50 mg/dL (> 105 nmol/L)b,c > 120 mg/dL: very high risk for myocardial infarction and aortic valve stenosis
Values in mmol/L were converted to mg/dL by multiplication with 38.6 for cholesterol and 88.5 for TG, followed by rounding to the nearest 5 mg/dL.
a TG thresholds based on assays with correction for endogenous glycerol. The free glycerol concentration in a sample, usually 1 mg/dL, equivalent to ~10 mg/dL
(0.11 mmol/L) of TG, can be ignored. Increased baseline glycerol concentrations can be found in patients with diabetes and chronic kidney disease and during
intravenous lipid infusion, and TG may be wrongly flagged in these patients unless glycerol-corrected TG assay is used.
b Threshold value for Lp(a) should represent ≥80th percentile of the population-specific Lp(a) assay.
c There is no consensus on which threshold value in mmol/L to be used for Lp(a); however, for conversion of Lp(a) concentrations in mg/dL to nmol/L, 13930
individuals from the Copenhagen General Population Study had measurements in both mg/dL and nmol/L by Denka Seiken assays distributed by Roche Diagnostics
(Rotkreuz, Switzerland). The correlation was done by linear regression with an R2 value of 0.996, and the conversion was done by the following equation: Lp(a),
nmol/L = 2.18*Lp(a), mg/dL–3.83 [3].
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additional tests, e.g., thyrotropin, haemoglobin A1c, liver enzymes and
creatinine/eGFR, if not already known to the clinician at first-time
screening [98].
Recommendation.
• Flagging of lipid profiles on laboratory reports should always be
based on decision thresholds. In children, reporting of reference
intervals is relevant.
• Extremely high concentrations should automatically trigger alerts to
initiate immediate diagnostic investigations.
11. Conclusion and future research priorities
The consensus-based recommendations of EAS and EFLM provide
guidance for the use of contemporary lipid, lipoprotein, and apolipo-
protein tests to assist clinicians in their strategies to prevent ASCVD
[1,2]. These recommendations take into account the strenghts and
weaknesses of the tests in terms of key criteria to become a medically
useful test, as defined by the EFLM Test Evaluation Working Group
[70].
Calculation of non-HDLC and RemnantC from the standard lipid
profile, ‘expanded’ testing of apoB and Lp(a), and ‘advanced’ testing of
LDLP have the potential to address clinical needs unmet with LDLC
testing and they can always be used in nonfasting samples. The research
priority is to investigate whether the diagnostic information provided
by ‘expanded’ or ‘advanced’ lipid profiles can sufficiently change clin-
ical management to reduce the risk (and cost) of ASCVD to a greater
extent than the standard LDLC-centered approach.
Diabetes and abdominal obesity, disorders that underlie the clinical
expression of complex dyslipidemias without elevated LDLC, are at-
taining epidemic proportions [11]. Hence, emerging and advanced li-
poprotein testing will likely become more and more useful in the future.
This underscores the need to standardize and validate advanced lipo-
protein tests, such as NMR- or ion mobility-based LDL- and VLDL-par-
ticle numbers and size [62,63], and multiplexed LC-MSMS apolipo-
protein profiles [68], which have the potential to become widely
available medical tests [99]. These novel technologies provide
complementary diagnostic information regarding the complex mole-
cular basis of dyslipidemias and, as such, can be used to explore and
evaluate precision medicine approaches for identifying better and in-
dividualized treatment options for patients at high risk of ASCVD [99].
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